Methylene blue, midodrine, and pseudoephedrine: a review of alternative agents for refractory hypotension in the intensive care unit - PubMed

Review

Methylene blue, midodrine, and pseudoephedrine: a review of alternative agents for refractory hypotension in the intensive care unit

Megan A Van Berkel et al. Crit Care Nurs Q. 2015 Oct-Dec.

Abstract

Hypotensive episodes are common among patients in the intensive care unit and can lead to multiorgan failure if uncontrolled. Fluid administration and continuous infusion of vasoactive agents are frequently used for management of hypotension; however, both therapies may be associated with adverse effects including pulmonary edema and tissue necrosis. In addition, availability of these first-line agents has been impacted by the increasing occurrence of drug shortages. Methylene blue, pseudoephedrine, and midodrine have been considered potential alternatives to standard therapy. These agents may not only be used when first-line agents are unavailable due to shortages, but they may also aid in reducing the cumulative dose of other vasoactive agents used. The purpose of this review was to discuss strategies for the safe and effective use of methylene blue, pseudoephedrine, and midodrine for the treatment of hypotension in the critically ill.

Similar articles

• Oral midodrine is effective for the treatment of hypotension associated with carotid artery stenting.

  Sharma S, Lardizabal JA, Bhambi B. Sharma S, et al. J Cardiovasc Pharmacol Ther. 2008 Jun;13(2):94-7. doi: 10.1177/1074248408317709. J Cardiovasc Pharmacol Ther. 2008. PMID: 18495904

• Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock.

  Tchen S, Sullivan JB. Tchen S, et al. J Crit Care. 2020 Jun;57:148-156. doi: 10.1016/j.jcrc.2020.02.011. Epub 2020 Feb 19. J Crit Care. 2020. PMID: 32145658 Review.

• Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions.

  Levine AR, Meyer MJ, Bittner EA, Berg S, Kalman R, Stanislaus AB, Ryan C, Ball SA, Eikermann M. Levine AR, et al. J Crit Care. 2013 Oct;28(5):756-62. doi: 10.1016/j.jcrc.2013.05.021. Epub 2013 Jul 8. J Crit Care. 2013. PMID: 23845791

• Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).

  Anstey MH, Wibrow B, Thevathasan T, Roberts B, Chhangani K, Ng PY, Levine A, DiBiasio A, Sarge T, Eikermann M. Anstey MH, et al. BMC Anesthesiol. 2017 Mar 21;17(1):47. doi: 10.1186/s12871-017-0339-x. BMC Anesthesiol. 2017. PMID: 28327122 Free PMC article. Clinical Trial.

• Efficacy and safety of midodrine in the treatment of dialysis-associated hypotension.

  Perazella MA. Perazella MA. Expert Opin Drug Saf. 2003 Jan;2(1):37-47. doi: 10.1517/14740338.2.1.37. Expert Opin Drug Saf. 2003. PMID: 12904123 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ingenta plc
  • Ovid Technologies, Inc.
  • Wolters Kluwer

• Medical

  • MedlinePlus Health Information